by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Biomarkers for Alzheimer’s disease neuropathologic change (ADNC) have been instrumental in developing effective disease-modifying therapeutics. However, to prevent/treat dementia effectively, we require biomarkers for non-AD...
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Blood-based biomarkers offer a promising approach for the detection of neuropathologies from repetitive head impacts (RHI). We evaluated plasma biomarkers of amyloid, tau, neurodegeneration, and inflammation in former football players. METHODS...
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Understanding the impact of biomarker-based dementia risk estimation in people with mild cognitive impairment (MCI) and their care partners is critical for patient care. METHODS MCI patients and study partners were counseled on Alzheimer’s...
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION It is important to understand the socioeconomic and medical determinants of subjective cognitive decline (SCD) at a population level in the United States. METHODS The primary outcomes are state-level rates of SCD and SCD-related functional...
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract Blood-based biomarkers (BBM) for Alzheimer’s disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid...
